- Home
- AXS vs IBRX Comparison
AXS vs IBRX Comparison
Compare AXS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXS | IBRX |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 8.2B |
| IPO Year | 2003 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AXS | IBRX |
|---|---|---|
| Price | $98.29 | $10.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $119.55 | $14.25 |
| AVG Volume (30 Days) | 621.9K | ★ 12.4M |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 3.29 | N/A |
| Revenue | ★ $6,563,678,000.00 | $113,288,000.00 |
| Revenue This Year | N/A | $99.59 |
| Revenue Next Year | $6.85 | $105.48 |
| P/E Ratio | $29.82 | ★ N/A |
| Revenue Growth | 10.17 | ★ 668.31 |
| 52 Week Low | $88.07 | $1.95 |
| 52 Week High | $119.99 | $12.43 |
Technical Indicators
Market Signals| Indicator | AXS | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 62.16 |
| Support Level | $97.54 | $6.68 |
| Resistance Level | $102.76 | $10.82 |
| Average True Range (ATR) | 1.73 | 0.59 |
| MACD | 0.52 | 0.05 |
| Stochastic Oscillator | 75.64 | 74.61 |
Price Performance
Historical ComparisonAbout AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States (U.S.), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of Insurance and Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States, and also has its presence in Ireland, Lloyd's of London, and Bermuda.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.